Preclinical Research
Prioritizing the Compassionate Care of Research Animals
The 3Rs of Animal Research
The 3Rs philosophy is the guiding principle for the Animal Welfare Program at Altasciences.
ISSUE NO. 16 — Microsampling in Drug Development
Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic drugs, metabolites, and biomarkers in preclinical and clinical research.
In preclinical research, microsampling technology supports the 3Rs of animal research, and allows for less intrusive blood collection procedures.
By definition, clinical microsampling reduces sample volume to less than or equal to 50 microlitres (μL) compared to conventional venipuncture wherein millilitres (mL) of blood volume is collected. In Altasciences’ experience, microsample volumes being analyzed are less than or equal to 20 μL, with some microsampling techniques as low as 5 μL.
In Issue 16 of The Altascientist, we explore the benefits, applications, and considerations of microsampling in preclinical, clinical, and bioanalytical research, including:
- regulatory considerations
- case study: Anti-Epileptic Drug Monitoring – Sample Preparation Using Impact-Assisted Extraction
- case study: Large Molecule – Determination of Rituximab Using a Surrogate Peptide Approach
2020 Year in Review
2020 has been quite a year! Each year, we strive to provide you with a more innovative, simplified, and seamless early phase drug development journey. And the past 12 months have been no exception.
Snuggle Wrap-based Restraint Method of Continuous Infusion in Juvenile Nonhuman Primates
Historical Control Database of Cynomolgus Macaque Spermatozoa
Assessment of Subcutaneous Radio-Telepathy Device Implantation in Cynomolgus Monkeys
Intraperitoneal Alfaxalone and Alfaxalone–Dexmedetomidine Anesthesia in Sprague–Dawley Rats (Rattus norvegicus)
ISSUE NO. 14 — Central Nervous SystemAs you work towards a successful New Drug Application (NDA) submission, there are many considerations that must be taken into account, specifically for central nervous system (CNS)-active drugs. Molecules or compounds that are centrally active (the parent drug or metabolite[s]), may require additional evaluations to characterize the drug effects and unique safety characteristics. In Issue 14 of The Altascientist, we look into the complex considerations of CNS-active drugs, including:
THE IMPORTANCE OF CLINICAL STUDIES FOR CNS-ACTIVE DRUGSCNS-active drugs have unique attributes that necessitate additional specialized study, such as: Determination of Pirfenidone and Metabolites in Rat Plasma by Coupling On-Line Fractionation with LC-MS-MS
Microsampling - Making a Difference in Drug Development
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Microsampling volumeBlood microsampling is a less invasive and simplified alternative to traditional venipuncture, and provides significant ad |